Publications
You can refine your search results by using the keyword search function.
| Publication date (day/month/year) | Title | Keywords | Authors | Journal |
|---|---|---|---|---|
| 2024-03-28 | hepatitis c virus, community survey, LMICs. | Gupta, N., Swindells, S., Scarsi, K.K., Furl, R., Thomas, D.L., Weld, E.D., Dountio Ofimboudem, J., Desalegn, H., Hamid, S., de la Torre Rosasa, A., Miranda, A.E., Owen, A., Rannard, S., Hiebert, L., Sun, K., & Ward, J.W. | Journal of Viral Hepatitis | |
| 2023-11-30 | Physiologically Based Pharmacokinetic Modelling of Cabotegravir Microarray Patches in Rats and Humans | HIV, cabotegravir, antiretroviral, microarray patches | Kinvig, H., Rajoli, R.K.R., Pertinez, H., Vora, L.K., Volpe-Zanutto, F., Donnelly, R., Rannard, S., Flexner, C., Siccardi, M., & Owen, A. | Pharmaceutics |
| 2023-11-23 | Lack of antiviral activity of probenecid in vitro and in Syrian golden hamsters | sars-cov-2, antiviral | Box, H.J., Sharp, J., Pennington, S.H., Kijak, E., Tatham, L., Caygill, C.H., Lopeman, R.C., Jeffreys, L.N., Herriott, J., Neary, M., Valentijn, A., Pertinez, H., Curley, P., Arshad, U,. Rajoli, R.K.R., Jochmans, D., Vangeel, L., Neyts, J., Chatelain, E., Escudié, F., Scandale, I., Rannard, S., Stewart, J.P., Biagini, G.A., & Owen, A. | Journal of Antimicrobial Chemotherapy |
| 2023-10-13 | An Open Label, Adaptive, Phase 1 Trial of High‐Dose Oral Nitazoxanide in Healthy Volunteers: An Antiviral Candidate for SARS‐CoV‐2 | sars-cov-2, nitazoxanide, antiviral | Walker, L.E., FitzGerald, R., Saunders, G., Lyon, R., Fisher, M., Martin, K., Eberhart, I., Woods, C., Ewings, S., Hale, C., Rajoli, R.K.R., Else, L., Dilly-Penchala, S., Amara, A., Lalloo, D.G., Jacobs, M., Pertinez, H., Hatchard, P., Waugh, R., Lawrence, M., Johnson, L., Fines, K., Reynolds, H., Rowland, T., Crook, R., Okenyi, E., Byrne, K., Mozgunov, P., Jaki, T., Khoo, S., Owen, A., Griffiths, G., & Fletcher, T.E. | Clinical Pharmacology & Therapeutics |
| 2023-10-27 | Chemoprophylactic Assessment of Combined Intranasal SARS-CoV-2 Polymerase and Exonuclease Inhibition in Syrian Golden Hamsters | sars-cov-2 | Gallardo-Toledo, E., Neary, M., Sharp, J., Herriott, J., Kijak, E., Bramwell, C., Curley, P., Arshad, U., Pertinez, H., Rajoli, R.K.R., Valentijn, A., Cox, H., Tatham, L., Kipar, A., Stewart, J., & Owen, A. | Viruses |
| 2023-10-25 | Development and validation of a liquid chromatographic-tandem mass spectrometric assay for the quantification of the direct acting antivirals glecaprevir and pibrentasvir in plasma | hepatitis c virus, glecaprevir, pibrenstasvir | Garza, K.Y., Pandey, A., & Marzinke, M.A. | Journal of Pharmaceutical and Biomedical Analysis |
| 2023-10-12 | Clinically relevant atovaquone-resistant human malaria parasites fail to transmit by mosquito | malaria, atovaquone | Balta, V.A., Stiffler, D., Sayeed, A., Tripathi, A.K., Elahi, R., Mlambo, G., Bakshi, R.P., Dziedzic, A.G., Jedlicka, A.E., Nenortas, E., Romero-Rodriguez, K., Canonizado, M.A., Mann, A., Owen, A., Sullivan, D.J. Prigge, S.T., Sinnis, P., & Shapiro, T.A. | Nature Communications |
| 2023-08-21 | Preferences of Patients and Providers in High-Burden Malaria Settings for Long-Acting Malaria Chemoprevention | malaria, survey | Scarsi, K.K., Sayles, H., Kapungu, K., Sifuna, P., Ippolito, M.M., Furl, R., Anderson, M.J., Dountio Ofimboudem, J., Chongwe, G., Hutter, J., Rannard, S., Owen, A., & Swindells, S. | The American Journal of Tropical Medicine and Hygiene |
| 2023-06-14 | Using Dynamic Oral Dosing of Rifapentine and Rifabutin to Simulate Exposure Profiles of Long-Acting Formulations in a Mouse Model of Tuberculosis Preventive Therapy | tuberculosis, rifapentine, rifabutin | Chang, Y.S., Li, S.Y., Pertinez, H., Betoudji, F., Lee, J., Rannard, S., Owen, A., Nuermberger, E.L., & Ammerman, N.C. | Antimicrobial Agents and Chemotherapy |
| 2022-11-21 | Prospects for Long-Acting Treatments for Hepatitis C | hepatitis c virus | Thomas, D. L., Owen, A., & Kiser, J. J. | Clinical Infectious Diseases |
| 2022-12-05 |
FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2 |
fxr inhibitor, sars-cov-2, ace2 | Brevini, T., Maes, M., Webb, G. J., John, B. V., Fuchs, C. D., Buescher, G., Sampaziotis, F. | Nature |
